DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that new clinical data from the INHALE-3 study first meal challenge will be presented at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence on March 6-9. INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.
Dr. Irl B. Hirsch, Professor of Medicine and Diabetes Treatment and Teaching Chair at the University of Washington and the INHALE-3 Study Protocol Chair, will provide an oral presentation focused on findings from a standardized meal challenge, including:
- Post-prandial glucose with inhaled insulin vs. subcutaneous rapid-acting analogue (RAA)
- Glucose outcomes including AUC and time to peak during the first two hours and beyond
- Frequency of post-meal hypoglycemia in both groups
"We are looking forward to the first slice of INHALE-3 data being presented here that builds upon findings from our pilot ABC study shared at last year's ATTD Conference," said Dr. Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation. "With ABC and this trial, we used a higher initial conversion dose for inhaled insulin than in ...